Negative serum pregnancy test within  days prior to registration for females of childbearing potential.
Negative pregnancy test of females with childbearing potential.
Females of childbearing potential must have a negative serum pregnancy test
For all females of childbearing potential, a negative serum pregnancy test must be obtained within  days prior to starting study treatment
A negative pregnancy test (for females of childbearing potential)
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least  years are not considered to be of childbearing potential)
Have a negative pregnancy test result at Screening for females of childbearing potential
Negative pregnancy test for females of childbearing potential
Females of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to start of first cycle of therapy
Serum or urine pregnancy test (for females of childbearing potential) negative ? days of starting treatment
Have a negative pregnancy test result at Screening for females of childbearing potential
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least  mIU/mL prior to starting therapy and prior to beginning another cycle (if applicable)
Negative urine or serum pregnancy test for females of childbearing potential
Negative serum pregnancy test at the time of enrollment for females of childbearing potential
Serum/urine pregnancy test (for females of childbearing potential) that is negative within  hours prior to initiation of first dose of treatment (a patient is of childbearing potential if, in the opinion of the investigator, she is biologically capable of having children and is sexually active)
Negative serum pregnancy test at the time of enrollment for females of childbearing potential
Females of childbearing potential must have a negative pregnancy test within  days prior to Study Day .
Serum or urine pregnancy test (for females of childbearing potential) negative at screening and at the baseline visit (before the patient may receive the investigational product)
Pregnant females are excluded; females of childbearing age/menstruating must confirm that either they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
For females of childbearing potential, a negative urine pregnancy test must be documented prior to randomization.
Females of childbearing potential must have a negative urine or serum pregnancy test within  week prior to the start of treatment
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least  years are not considered to be of childbearing potential)
Females of childbearing potential must have negative results for pregnancy test performed:
Not pregnant - females of childbearing potential must have a negative pregnancy test within  days of apheresis
DONOR: Not pregnant - females of childbearing potential must have a negative pregnancy test within  days of apheresis
Serum/urine pregnancy test (for females of childbearing potential) that is negative at screening and immediately prior to initiation of treatment (first dose).
Serum pregnancy test (for females of childbearing potential) negative at screening
Pregnant or breast feeding; the agents used in this study include pregnancy category D: known to cause harm to a fetus; females of childbearing potential must have a negative pregnancy test prior to starting therapy
Females with childbearing potential must have had a negative urine or serum pregnancy test =<  days before the first dose of deferasirox and must also not be breastfeeding
Negative pregnancy test in females of reproductive age
Pregnant or breast feeding; females of childbearing potential must have a negative pregnancy test prior to starting therapy
Females of childbearing potential must have a negative pregnancy test and agree to use contraception during on-study protocol treatment.
Serum or urine pregnancy test (for females of childbearing potential) negative =<  days of registration
ENTRECTINIB EXCLUSION CRITERIA: Females of childbearing potential must have a negative serum pregnancy test during screening and must not be breastfeeding or intending to become pregnant during the study
Females of childbearing potential must have negative serum or urine pregnancy test.
Females with childbearing potential must have a negative serum pregnancy test within  days prior to treatment start
For all females of childbearing potential, a negative pregnancy test must be obtained within  days before starting study treatment
For females of childbearing potential, a negative serum pregnancy test must be documented within  hours of receiving the first dose of vorinostat
Females of childbearing potential must have a negative urine pregnancy test at screening and be willing to have additional urine pregnancy tests during the study; females considered not of childbearing potential include those who have been in menopause at least  years, or had tubal ligation at least  year prior to screening, or who have had total hysterectomy
Females of childbearing potential must have a negative pregnancy test within  week prior to treatment with I-MIBG
Pregnant females are excluded; women of childbearing age/menstruating must confirm they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
Females of childbearing potential must not be pregnant; this will be confirmed by a negative serum pregnancy test within  days prior to starting study treatment
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least  mIU/mL within - days prior to study entry
For females of childbearing potential, a negative pregnancy test must be documented prior to randomization
Females of childbearing potential must have negative serum or urine pregnancy test within  days prior to study entry; the effects of lapatinib on the developing human fetus are unknown; however, bevacizumab is known to be teratogenic and detrimental to fetal development and endometrial proliferation, thereby having a negative effect on fertility
Pregnant or breastfeeding; females of childbearing potential must have a negative pregnancy test prior to starting therapy
For females, a negative pregnancy test
Negative serum or urine pregnancy test (females of childbearing potential only).
DONORS: Not pregnant - females of childbearing potential must have a negative pregnancy test within  days of mobilization start
Females of childbearing potential must have a negative serum pregnancy test at screening
Females of childbearing potential must have a negative pregnancy test within  days of being registered for protocol therapy
Pregnant or breast feeding; the agents used in this study have the potential to harm a fetus; radiation is a known teratogen; there is insufficient information regarding potential for fetal harm during immunotherapy at this time; biological females of childbearing potential must have a negative pregnancy test within  days of registration
Negative pregnancy test for females of childbearing potential
Females of childbearing potential that do not have a negative pregnancy test.
Negative Serum pregnancy test for females of childbearing potential
A negative pregnancy test (for females of childbearing potential).
Females with childbearing potential: Have had a negative serum pregnancy test ? days before the first dose of study drug and also must not be breastfeeding.
Females of childbearing potential must have a negative serum pregnancy test
Females of childbearing potential have a negative serum pregnancy test (preceding  hours of first day of BBI treatment).
Females of childbearing potential must have a negative serum or urine pregnancy test prior to patient registration
Negative serum pregnancy test in females of childbearing potential
Negative pregnancy test for females of childbearing potential
Females of childbearing potential must have a negative serum pregnancy test
Negative pregnancy test for females of childbearing potential
For females of childbearing potential, must have a negative pregnancy test
Females of childbearing potential must have a negative serum pregnancy test within  days of treatment
Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment.
Pregnant as determined by a positive serum pregnancy test within  days prior to registration on study (for females of childbearing potential)
Females should be using adequate contraceptive measures should not be breast feeding, and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential
Females of childbearing potential must have a negative serum or urine pregnancy test at screening
Females of childbearing potential should have a negative pregnancy test
Females of childbearing potential have a negative serum pregnancy test.
Negative urine or serum pregnancy test for females of childbearing potential
Females who are breastfeeding or pregnant. For females of childbearing potential, a negative screening pregnancy test must be obtained within  hours before the first dose of study drug
For females with reproductive potential: a negative serum pregnancy test
Females of childbearing potential must have a negative serum pregnancy test
Females of childbearing potential must have a negative serum pregnancy test.
Pregnant females are excluded; women of childbearing age/menstruating must confirm that they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
Females of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of treatment
Negative pregnancy test in females of reproductive age
Both men and women may be enrolled; premenopausal females must have a negative pregnancy test prior to treatment and lactating females will have to discontinue breast feeding to be eligible
Females of childbearing potential must have a negative pregnancy test within  days of being registered for protocol therapy
Females with childbearing potential must have had a negative serum pregnancy test less than or equal to  days prior to the first dose of study drug
Females of childbearing potential must have a negative pregnancy test (by serum beta-HCG) within  days prior to the start of treatment.
Pregnant females are excluded; women of childbearing age/menstruating must confirm that they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
Serum/urine pregnancy test (for females of childbearing potential) negative at screening and before the patient will receive the study treatment.
Females of childbearing potential must undergo pregnancy testing based on the frequency outlined in Pregnancy Prevention Risk Minimization Plan and pregnancy results must be negative.
Negative serum pregnancy test in females of childbearing potential
Negative serum pregnancy test for females
Females of childbearing potential must have a negative pregnancy test at screening; patients taking oral contraceptives should use an additional method of contraception
Negative pregnancy test for Females of childbearing potential.
Females of childbearing potential must have a negative pregnancy test result within  days prior to the first dose of study drug.
Females of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to start of ipilimumab
Females of childbearing potential must have a negative serum pregnancy test
Females (childbearing potential): Have had a negative serum pregnancy test before the first dose of study drug and not be breast-feeding.
Females of childbearing potential must have a negative pregnancy test within  days prior to registration for protocol therapy.
Females of childbearing potential must have a negative serum pregnancy test at screening
In addition, women of childbearing potential must consent to use adequate contraception throughout protocol therapy; females of childbearing potential must have a negative urine pregnancy test =<  days prior to registration
Females of childbearing potential have a negative pregnancy test within  hours prior to initiating study drug dosing
Pregnant females (women of childbearing potential must have a negative serum pregnancy test prior to enrollment)
Pregnancy or nursing: All females of childbearing age must have a negative serum or urine pregnancy test <  days before study drug administration
For females of childbearing potential, a negative serum pregnancy test must be documented prior to enrollment
Serum pregnancy test negative for females of childbearing potential
Females of childbearing potential must have a negative pregnancy test; sexually active patients must agree to use contraception prior to, during, and  days after last dose
Negative serum pregnancy test at the time of enrollment for females of childbearing potential
Negative serum pregnancy test for females of childbearing potential
Females of childbearing potential must have a negative serum pregnancy test
All females of childbearing age must have a negative pregnancy test before beginning the study
